Search
Research
Associations between ethnicity, social contact, and pneumococcal carriage three years post-PCV10 in FijiIndigenous iTaukei had greater frequency and intensity of contact compared with Fijians of Indian Descent
Research
B Part of It School Leaver protocol: an observational study to assess the impact of a meningococcal serogroup B vaccine programme on carriage of Neisseria meningitidisThis study will assess the impact of MenB vaccine (4CMenB) on carriage prevalence in school leavers in South Australia
Research
Excess respiratory mortality and hospitalizations associated with influenza in Australia, 2007-2015Influenza is the most common vaccine-preventable disease in Australia, causing significant morbidity and mortality. We assessed the burden of influenza across all ages in terms of influenza-associated mortality and hospitalizations using national mortality, hospital-discharge and influenza surveillance data.
Research save lives and contains the spread of COVID-19.
News & Events
It’s not just physical illness that will have an impact: A ground-breaking study is investigating the effect of COVID-19 on community wellbeingIn an Australian-first study, researchers at The Kids Research Institute Australia are investigating the effects of COVID-19 on the wellbeing of more than 2,000 families in the northern suburbs of Perth, measuring their perceived stress, financial hardship and family functioning during the pandemic.
Research
Management and outcomes of children hospitalised with COVID-19 including incidental and nosocomial infections in Australia 2020–2023: A national surveillance studyManagement and outcomes of children hospitalised with acute SARS-CoV-2 infection may differ throughout the pandemic or with admission type (clinical COVID-19, incidental COVID-19 or nosocomial infection).
Research
Estimating measures to reduce the transmission of SARS-CoV-2 in Australia to guide a ‘National Plan’ to reopeningThe availability of COVID-19 vaccines promised a reduction in the severity of disease and relief from the strict public health and social measures (PHSMs) imposed in many countries to limit spread and burden of COVID-19. We were asked to define vaccine coverage thresholds for Australia's transition to easing restrictions and reopening international borders.
Research
Randomised controlled trials of behavioural nudges delivered through text messages to increase influenza and COVID-19 vaccines among pregnant women (the EPIC study): study protocolInfluenza and COVID-19 infections during pregnancy may have serious adverse consequences for women as well as their infants. However, uptake of influenza and COVID-19 vaccines during pregnancy remains suboptimal. This study aims to assess the effectiveness of a multi-component nudge intervention to improve influenza and COVID-19 vaccine uptake among pregnant women.
Research
Persistence of the immune responses and cross-neutralizing activity with Variants of Concern following two doses of adjuvanted SCB-2019 COVID-19 vaccineWe have previously reported the safety and immunogenicity four weeks after two doses of the Clover COVID-19 vaccine candidate, SCB-2019, a stabilized pre-fusion form of the SARS-CoV-2 S-protein (S-trimer). We now report persistence of antibodies up to 6 months after vaccination, and cross-neutralization titers against three Variants of Concern.
Research
Maternal influenza vaccination and child mortality: Longitudinal, population-based linked cohort studyInfluenza vaccination is recommended to protect mothers and their infants from influenza. Few studies have evaluated the association between maternal influenza vaccination and child mortality. We aimed to evaluate the association between in utero exposure to seasonal inactivated influenza vaccine (IIV) and mortality among young children.
Research
Severe winter asthma exacerbations can be prevented by omalizumab, but there is no carryover effect.Recurrent severe asthma exacerbations are associated with decreased lung growth or accelerated loss of long function and add substantially to cost and morbidity
Research
Continuous active surveillance of adverse events following immunisation using SMS technologyAutomated SMS-based reporting can facilitate sustainable, real-time, monitoring of adverse reactions and early identification of potential vaccine safety issues
News & Events
Worried about your child getting coronavirus? Here’s what you need to knowComparatively few children have tested positive for coronavirus (COVID-19). Here’s what we know so far about how children are affected.
Research
Changing rules, recommendations, and risks: COVID-19 vaccination decisions and emotions during pregnancyAs COVID-19 vaccinations rolled out globally from late 2020, rules and recommendations regarding vaccine use in pregnancy shifted rapidly. Pre-registration COVID-19 vaccine trials excluded those who were pregnant. Initial Australian medical advice did not routinely recommend COVID-19 vaccines in pregnancy, due to limited safety data and little perceived risk of local transmission.
Research
The seroprevalence of SARS-CoV-2-specific antibodies in Australian children: A crosssectional studyFollowing reduction of public health and social measures concurrent with SARS-CoV-2 Omicron emergence in late 2021 in Australia, COVID-19 case notification rates rose rapidly. As rates of direct viral testing and reporting dropped, true infection rates were most likely to be underestimated.
Research
Defining the pediatric response to SARS-CoV-2 variantsThe global population has been severely affected by the coronavirus disease 2019 (COVID-19) pandemic, however, with older age identified as a risk factor, children have been underprioritized. This article discusses the factors contributing to the less severe response observed in children following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including, differing viral entry receptor expression and immune responses.
Research
Core protocol for the adaptive Platform Trial In COVID-19 Vaccine priming and BOOsting (PICOBOO)The need for coronavirus 2019 (COVID-19) vaccination in different age groups and populations is a subject of great uncertainty and an ongoing global debate. Critical knowledge gaps regarding COVID-19 vaccination include the duration of protection offered by different priming and booster vaccination regimens in different populations, including homologous or heterologous schedules.